about
Somatostatin analogues, dopamine agonists or growth hormone antagonists for pituitary adenoma-induced acromegalySomatostatin analogues, dopamine agonists or growth hormone antagonists for pituitary adenoma-induced acromegalyPituitary somatostatin receptor signalingPasireotide: a novel treatment for patients with acromegalyThe effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyClinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumorsBright fluorescence monitoring system utilizing Zoanthus sp. green fluorescent protein (ZsGreen) for human G-protein-coupled receptor signaling in microbial yeast cellsImportance of asparagine residues at positions 13 and 26 on the amino-terminal domain of human somatostatin receptor subtype-5 in signalling.Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience ReportClinical, quality of life, and economic value of acromegaly disease controlComparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegalyAlteration of somatostatin receptor 2 expression in canine mammary gland tumor.Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin AnaloguesMedical therapy of acromegaly in Turkey.The changing face of acromegaly--advances in diagnosis and treatment.Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin ReceptorsEmerging drugs for acromegaly.Somatostatin receptor ligands in the treatment of acromegaly.Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells.Desensitization treatment for hypersensitivity reaction to octreotide in an acromegalic patient.Somatostatin receptor activation is involved in the control of daily torpor in a seasonal mammal.Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.Immunohistochemical distribution of somatostatin and somatostatin receptor subtypes (SSTR1-5) in hypothalamus of ApoD knockout mice brain.Simultaneous method for analyzing dimerization and signaling of G-protein-coupled receptor in yeast by dual-color reporter system.Novel Somatostatin Receptor Ligands Therapies for Acromegaly.Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial.New directions in pharmacological treatment of acromegaly
P2860
Q24188346-22BFF7C5-FA4F-4222-BCA9-235814B795EAQ24239834-D108D100-824E-423D-B6E9-1505A9152606Q24631604-96A65A85-A4EA-4E4B-A3A7-6254F83E1EE3Q26774437-269284AD-3120-46CD-8780-0FDC6363C248Q26796357-265C4D9D-3DC5-447F-B68C-2210A9187EC8Q28069632-57A06473-10BB-4667-9CBA-E80BCC210AEEQ28536254-D4CFDB7D-1167-4D8A-A1A4-C03F95F06EFCQ33537659-D88D91B3-46FB-47C6-B735-9BB4CE5415FAQ33592680-4B7A15CC-18AB-4FE8-A838-F431F5C751C9Q35137675-6092F439-24CF-4594-83BF-A0DAD7697807Q36236809-927758D6-6BBD-4432-9A8D-C29E5FDB0AFAQ36263767-1D7A164F-846E-4D82-B055-788646B0E97CQ37726440-5738408C-ADBB-4185-8085-92C284358FA6Q37798655-2C41C7DD-F3C0-42FA-B63C-2DE40DAA4C69Q38021680-AD48B111-EB79-4962-B006-EBB627038CE2Q38166623-6835255E-3E4D-401C-9235-ABB4A05CF8B7Q38176659-CB720E2C-BA3B-46B0-A68B-84C85C067F21Q39125449-63787449-F878-4EF7-95C3-FE407195761FQ39673688-11E55F11-5D90-4B79-ADA5-86CE451A8B2AQ39739369-46004A9C-EBB1-445D-B429-EB20FA83B576Q42842968-F1C4DF1E-3425-425D-9A02-48F910EAD41FQ47726453-31EBF8AE-97F9-48E9-B497-827E8FBF38C1Q48088961-8A525DCA-E71E-4EB4-80BF-795A0D859F47Q48181953-64B7B7E4-B765-40A6-BFA7-8BE203B2B565Q48515460-63191774-BB51-4FE9-B20C-63AA0C25561AQ50470951-209848E7-EB84-4405-8514-8CBA9CF1FB7DQ52643700-F1D6B2C0-4DD9-4A28-ADDD-6D0FBB02AF6DQ54542028-5B9823EA-3F9A-4A97-9EFB-E55EB15B10F5Q58897890-3546FC8F-A3EB-49E4-BDCA-D9A6DCCA1148
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Somatostatin agonists for treatment of acromegaly.
@en
Somatostatin agonists for treatment of acromegaly.
@nl
type
label
Somatostatin agonists for treatment of acromegaly.
@en
Somatostatin agonists for treatment of acromegaly.
@nl
prefLabel
Somatostatin agonists for treatment of acromegaly.
@en
Somatostatin agonists for treatment of acromegaly.
@nl
P2860
P1476
Somatostatin agonists for treatment of acromegaly.
@en
P2093
Anat Ben-Shlomo
Shlomo Melmed
P2860
P304
P356
10.1016/J.MCE.2007.11.024
P577
2007-11-29T00:00:00Z